Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Travel burden associated with rare cancers: The example of Merkel cell carcinoma.

Jain R, Menzin J, Lachance K, McBee P, Phatak H, Nghiem PT.

Cancer Med. 2019 May;8(5):2580-2586. doi: 10.1002/cam4.2085. Epub 2019 Apr 5.

2.

Correction to: Gene therapies in canine models for Duchenne muscular dystrophy.

Nghiem PP, Kornegay JN.

Hum Genet. 2019 May;138(5):491. doi: 10.1007/s00439-019-01982-1.

PMID:
30783825
3.

Gene therapies in canine models for Duchenne muscular dystrophy.

Nghiem PP, Kornegay JN.

Hum Genet. 2019 May;138(5):483-489. doi: 10.1007/s00439-019-01976-z. Epub 2019 Feb 7. Review. Erratum in: Hum Genet. 2019 Feb 19;:.

PMID:
30734120
4.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
5.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M.

Cancer Immunol Immunother. 2019 Apr;68(4):609-618. doi: 10.1007/s00262-018-02295-4. Epub 2019 Feb 5.

6.

Tuberculosis following PD-1 blockade for cancer immunotherapy.

Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, Nieva JJ, Cheever MA, Nghiem PT, Sharon E.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702.

PMID:
30651320
7.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P.

J Immunother Cancer. 2018 Nov 27;6(1):131. doi: 10.1186/s40425-018-0450-7.

8.

T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes.

Bentzen AK, Such L, Jensen KK, Marquard AM, Jessen LE, Miller NJ, Church CD, Lyngaa R, Koelle DM, Becker JC, Linnemann C, Schumacher TNM, Marcatili P, Nghiem P, Nielsen M, Hadrup SR.

Nat Biotechnol. 2018 Nov 19. doi: 10.1038/nbt.4303. [Epub ahead of print]

PMID:
30451992
9.

The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.

Harms PW, Harms KL, Moore PS, DeCaprio JA, Nghiem P, Wong MKK, Brownell I; International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group.

Nat Rev Clin Oncol. 2018 Dec;15(12):763-776. doi: 10.1038/s41571-018-0103-2. Review.

10.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Giraldo NA, Nguyen P, Engle EL, Kaunitz GJ, Cottrell TR, Berry S, Green B, Soni A, Cuda JD, Stein JE, Sunshine JC, Succaria F, Xu H, Ogurtsova A, Danilova L, Church CD, Miller NJ, Fling S, Lundgren L, Ramchurren N, Yearley JH, Lipson EJ, Cheever M, Anders RA, Nghiem PT, Topalian SL, Taube JM.

J Immunother Cancer. 2018 Oct 1;6(1):99. doi: 10.1186/s40425-018-0404-0.

11.

Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.

Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, Valente WJ, Koelle SJ, Church CD, Vandeven N, Thomas H, Colunga AG, Iyer JG, Yee C, Kulikauskas R, Koelle DM, Pierce RH, Bielas JH, Greenberg PD, Bhatia S, Gottardo R, Nghiem P, Chapuis AG.

Nat Commun. 2018 Sep 24;9(1):3868. doi: 10.1038/s41467-018-06300-3.

12.

Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival.

Cook M, Baker K, Redman M, Lachance K, Nguyen MH, Parvathaneni U, Bhatia S, Nghiem P, Tseng YD.

Am J Clin Oncol. 2019 Jan;42(1):82-88. doi: 10.1097/COC.0000000000000482.

PMID:
30211723
13.

Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma.

Tseng YD, Nguyen MH, Baker K, Cook M, Redman M, Lachance K, Bhatia S, Liao JJ, Apisarnthanarax S, Nghiem PT, Parvathaneni U.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):330-339. doi: 10.1016/j.ijrobp.2018.05.075. Epub 2018 Jun 5.

PMID:
30191867
14.

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.

Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S.

J Immunother Cancer. 2018 Aug 31;6(1):82. doi: 10.1186/s40425-018-0396-9.

15.

One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data.

Paulson KG, Nghiem P.

J Am Acad Dermatol. 2019 Jun;80(6):1758-1760. doi: 10.1016/j.jaad.2018.08.021. Epub 2018 Aug 27. No abstract available.

PMID:
30165170
16.

Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma.

Bhatia S, Miller NJ, Lu H, Longino NV, Ibrani D, Shinohara MM, Byrd DR, Parvathaneni U, Kulikauskas R, Ter Meulen J, Hsu FJ, Koelle DM, Nghiem P.

Clin Cancer Res. 2019 Feb 15;25(4):1185-1195. doi: 10.1158/1078-0432.CCR-18-0469. Epub 2018 Aug 9.

PMID:
30093453
17.

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma.

Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Ødum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC.

Clin Cancer Res. 2018 Dec 1;24(23):5873-5882. doi: 10.1158/1078-0432.CCR-18-1184. Epub 2018 Jul 30.

PMID:
30061360
18.

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM.

J Natl Compr Canc Netw. 2018 Jun;16(6):742-774. doi: 10.6004/jnccn.2018.0055.

PMID:
29891526
19.

A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.

Mata López S, Hammond JJ, Rigsby MB, Balog-Alvarez CJ, Kornegay JN, Nghiem PP.

Skelet Muscle. 2018 May 29;8(1):16. doi: 10.1186/s13395-018-0162-1.

20.

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.

Tarabadkar ES, Thomas H, Blom A, Parvathaneni U, Olencki T, Nghiem P, Bhatia S.

Am J Case Rep. 2018 Apr 30;19:505-511. doi: 10.12659/AJCR.908649.

21.

Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.

Gavvovidis I, Leisegang M, Willimsky G, Miller N, Nghiem P, Blankenstein T.

Clin Cancer Res. 2018 Aug 1;24(15):3644-3655. doi: 10.1158/1078-0432.CCR-17-2661. Epub 2018 Apr 18.

PMID:
29669806
22.

The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment.

Stang A, Becker JC, Nghiem P, Ferlay J.

Eur J Cancer. 2018 May;94:47-60. doi: 10.1016/j.ejca.2018.02.003. Epub 2018 Mar 20.

23.

Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy.

Schneider SM, Sridhar V, Bettis AK, Heath-Barnett H, Balog-Alvarez CJ, Guo LJ, Johnson R, Jaques S, Vitha S, Glowcwski AC, Kornegay JN, Nghiem PP.

Mol Imaging Biol. 2018 Oct;20(5):780-788. doi: 10.1007/s11307-018-1174-2.

24.

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P.

J Immunother Cancer. 2018 Jan 19;6(1):7. doi: 10.1186/s40425-017-0310-x.

25.

Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival.

Vandeven N, Lewis CW, Makarov V, Riaz N, Paulson KG, Hippe D, Bestick A, Doumani R, Marx T, Takagishi S, Chan TA, Choi J, Nghiem P.

Clin Cancer Res. 2018 Feb 15;24(4):963-971. doi: 10.1158/1078-0432.CCR-17-1678. Epub 2017 Dec 15.

26.

Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Colunga A, Pulliam T, Nghiem P.

Clin Cancer Res. 2018 May 1;24(9):2035-2043. doi: 10.1158/1078-0432.CCR-17-0439. Epub 2017 Dec 7. Review.

27.

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Becker JC, Stang A, Hausen AZ, Fischer N, DeCaprio JA, Tothill RW, Lyngaa R, Hansen UK, Ritter C, Nghiem P, Bichakjian CK, Ugurel S, Schrama D.

Cancer Immunol Immunother. 2018 Mar;67(3):341-351. doi: 10.1007/s00262-017-2099-3. Epub 2017 Nov 30. Review.

28.

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL.

Oncoimmunology. 2017 Aug 31;6(10):e1338237. doi: 10.1080/2162402X.2017.1338237. eCollection 2017. Review.

29.

Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.

Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, Harms KL, Thompson JA, Bhatia S, Stang A, Nghiem P.

J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2. doi: 10.1016/j.jaad.2017.10.028. Epub 2017 Nov 2.

30.

Merkel cell carcinoma.

Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P.

Nat Rev Dis Primers. 2017 Oct 26;3:17077. doi: 10.1038/nrdp.2017.77. Review.

31.

Changes in Muscle Metabolism are Associated with Phenotypic Variability in Golden Retriever Muscular Dystrophy.

Nghiem PP, Bello L, Stoughton WB, López SM, Vidal AH, Hernandez BV, Hulbert KN, Gourley TR, Bettis AK, Balog-Alvarez CJ, Heath-Barnett H, Kornegay JN.

Yale J Biol Med. 2017 Sep 25;90(3):351-360. eCollection 2017 Sep.

32.

CD200 Expression in Neuroendocrine Neoplasms.

Love JE, Thompson K, Kilgore MR, Westerhoff M, Murphy CE, Papanicolau-Sengos A, McCormick KA, Shankaran V, Vandeven N, Miller F, Blom A, Nghiem PT, Kussick SJ.

Am J Clin Pathol. 2017 Sep 1;148(3):236-242. doi: 10.1093/ajcp/aqx071.

33.

Osteopontin is linked with AKT, FoxO1, and myostatin in skeletal muscle cells.

Nghiem PP, Kornegay JN, Uaesoontrachoon K, Bello L, Yin Y, Kesari A, Mittal P, Schatzberg SJ, Many GM, Lee NH, Hoffman EP.

Muscle Nerve. 2017 Dec;56(6):1119-1127. doi: 10.1002/mus.25752. Epub 2017 Aug 13.

34.

Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck.

Takagishi SR, Marx TE, Lewis C, Tarabadkar ES, Juhlin ID, Blom A, Iyer JG, Liao JJ, Tseng YD, Fu T, Nghiem P, Parvathaneni U.

Adv Radiat Oncol. 2016 Oct 20;1(4):244-251. doi: 10.1016/j.adro.2016.10.003. eCollection 2016 Oct-Dec.

35.

Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.

Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC.

Sci Rep. 2017 May 23;7(1):2290. doi: 10.1038/s41598-017-02608-0.

36.

Response.

Bhatia S, Storer BE, Nghiem P.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx053. No abstract available.

PMID:
28423401
37.

DGCR8 Mediates Repair of UV-Induced DNA Damage Independently of RNA Processing.

Calses PC, Dhillon KK, Tucker N, Chi Y, Huang JW, Kawasumi M, Nghiem P, Wang Y, Clurman BE, Jacquemont C, Gafken PR, Sugasawa K, Saijo M, Taniguchi T.

Cell Rep. 2017 Apr 4;19(1):162-174. doi: 10.1016/j.celrep.2017.03.021.

38.

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.

Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC.

Future Oncol. 2017 Jun;13(14):1263-1279. doi: 10.2217/fon-2017-0072. Epub 2017 Mar 28. Review.

39.

Biomedical Research as a Team Sport.

Nghiem P.

J Invest Dermatol. 2017 Apr;137(4):783-786. doi: 10.1016/j.jid.2017.01.022. No abstract available.

40.

Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists.

Tseng YD, Apisarnthanarax S, Liao JJ, Bhatia S, Nghiem PT, Parvathaneni U.

Expert Rev Anticancer Ther. 2017 Mar;17(3):281-287. doi: 10.1080/14737140.2017.1285233. Epub 2017 Jan 29.

PMID:
28103445
41.

Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, Jing L, Shinohara M, Gavvovidis I, Willimsky G, McIntosh M, Blankenstein T, Koelle DM, Nghiem P.

Cancer Immunol Res. 2017 Feb;5(2):137-147. doi: 10.1158/2326-6066.CIR-16-0210. Epub 2017 Jan 16.

42.

Whole genome sequencing reveals a 7 base-pair deletion in DMD exon 42 in a dog with muscular dystrophy.

Nghiem PP, Bello L, Balog-Alvarez C, López SM, Bettis A, Barnett H, Hernandez B, Schatzberg SJ, Piercy RJ, Kornegay JN.

Mamm Genome. 2017 Apr;28(3-4):106-113. doi: 10.1007/s00335-016-9675-2. Epub 2016 Dec 27.

43.

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.

Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P.

Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.

44.

Use of the six-minute walk test to characterize golden retriever muscular dystrophy.

Acosta AR, Van Wie E, Stoughton WB, Bettis AK, Barnett HH, LaBrie NR, Balog-Alvarez CJ, Nghiem PP, Cummings KJ, Kornegay JN.

Neuromuscul Disord. 2016 Dec;26(12):865-872. doi: 10.1016/j.nmd.2016.09.024. Epub 2016 Oct 3.

PMID:
27818009
45.

Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection.

Moshiri AS, Doumani R, Yelistratova L, Blom A, Lachance K, Shinohara MM, Delaney M, Chang O, McArdle S, Thomas H, Asgari MM, Huang ML, Schwartz SM, Nghiem P.

J Invest Dermatol. 2017 Apr;137(4):819-827. doi: 10.1016/j.jid.2016.10.028. Epub 2016 Nov 1.

46.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.

Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.

47.

OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages.

Many GM, Yokosaki Y, Uaesoontrachoon K, Nghiem PP, Bello L, Dadgar S, Yin Y, Damsker JM, Cohen HB, Kornegay JN, Bamman MM, Mosser DM, Nagaraju K, Hoffman EP.

Exp Physiol. 2016 Oct 1;101(10):1285-1300. doi: 10.1113/EP085768. Epub 2016 Sep 24.

48.

Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma.

Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, Ma C, Bestick A, Parvathaneni U, Bhatia S, Nghiem P.

Cancer Med. 2016 Sep;5(9):2294-301. doi: 10.1002/cam4.815. Epub 2016 Jul 19.

49.

Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy.

Vandeven NA, Nghiem P.

J Oncol Pract. 2016 Jul;12(7):649-50. doi: 10.1200/JOP.2016.014498. No abstract available.

50.

Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Vandeven N, Nghiem P.

Immunotherapy. 2016 Jul;8(8):907-21. doi: 10.2217/imt-2016-0009. Review.

Supplemental Content

Loading ...
Support Center